Frontiers in Cardiovascular Medicine (Nov 2020)

p90RSK-MAGI1 Module Controls Endothelial Permeability by Post-translational Modifications of MAGI1 and Hippo Pathway

  • Rei J. Abe,
  • Hannah Savage,
  • Masaki Imanishi,
  • Priyanka Banerjee,
  • Sivareddy Kotla,
  • Jesus Paez-Mayorga,
  • Jack Taunton,
  • Keigi Fujiwara,
  • Jong Hak Won,
  • Syed Wamique Yusuf,
  • Nicolas L. Palaskas,
  • Jose Banchs,
  • Steven H. Lin,
  • Keri L. Schadler,
  • Jun-ichi Abe,
  • Nhat-Tu Le

DOI
https://doi.org/10.3389/fcvm.2020.542485
Journal volume & issue
Vol. 7

Abstract

Read online

Previously, we reported that post-translational modifications (PTMs) of MAGI1, including S741 phosphorylation and K931 de-SUMOylation, both of which are regulated by p90RSK activation, lead to endothelial cell (EC) activation. However, roles for p90RSK and MAGI1-PTMs in regulating EC permeability remain unclear despite MAGI1 being a junctional molecule. Here, we show that thrombin (Thb)-induced EC permeability, detected by the electric cell-substrate impedance sensing (ECIS) based system, was decreased by overexpression of dominant negative p90RSK or a MAGI1-S741A phosphorylation mutant, but was accelerated by overexpression of p90RSK, siRNA-mediated knockdown of magi1, or the MAGI1-K931R SUMOylation mutant. MAGI1 depletion also increased the mRNA and protein expression of the large tumor suppressor kinases 1 and 2 (LATS1/2), which inhibited YAP/TAZ activity and increased EC permeability. Because the endothelial barrier is a critical mediator of tumor hypoxia, we also evaluated the role of p90RSK activation in tumor vessel leakiness by using a relatively low dose of the p90RSK specific inhibitor, FMK-MEA. FMK-MEA significantly inhibited tumor vessel leakiness at a dose that does not affect morphology and growth of tumor vessels in vivo. These results provide novel insights into crucial roles for p90RSK-mediated MAGI1 PTMs and the Hippo pathway in EC permeability, as well as p90RSK activation in tumor vessel leakiness.

Keywords